AZ recruits ImaginAb in CD8 ImmunoPET deal

PharmaTimes | March 30, 2020

AstraZeneca has revealed plans to signed a multi-year non-exclusive license agreement with ImaginAb, in order to license the latter’s ImaginAb’s CD8 ImmunoPET technology. The companies say that under the terms of the agreement, the technology will be used in AstraZeneca’s clinical trials in Europe and North America to facilitate clinical development of AstraZeneca’s novel immunotherapies and to advance the clinical utility of ImaginAb’s CD8 ImmunoPET. CD8 ImmunoPET minibody works by binding CD8 receptor on human T cells and is used for non-invasive PET imaging of CD8 T cells in patients.

Spotlight

The material included in these modules serves many interests by facilitating understanding of construct, dynamics, and influences affecting regulatory policies and corporate decision-making that ultimately determine access, availability, and safety of pharmaceutical products.

Spotlight

The material included in these modules serves many interests by facilitating understanding of construct, dynamics, and influences affecting regulatory policies and corporate decision-making that ultimately determine access, availability, and safety of pharmaceutical products.

Related News

BUSINESS INSIGHTS

Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.

Glaukos | September 20, 2021

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Attillaps Holdings, Inc. under which Attillaps has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compounds that target the eradication of Demodex mites, which are the root cause of Demodex blepharitis and often associated with meibomian gland dysfunction and related ophthalmic diseases. Demodex blepharitis and Demodex-driven meibomian gland dysfunction are caused by an infestation of Demodex mites, the most common ectoparasite found on human skin. Demodex blepharitis is characterized by eyelid inflammation and irritation resulting in eyelid redness, discomfort and debris. Demodex-driven meibomian gland dysfunction is characterized by decreased lipid secretion into the tear film and is a leading cause of dry eye disease. Under the agreement, Glaukos has the exclusive global right to research, develop, manufacture and commercialize products using certain acetylcholinesterase (AChE) inhibitors for the treatment of ophthalmic diseases caused by Demodex mites. Attillaps’ lead compounds have demonstrated promising in-vitro results in preclinical settings. We are incredibly excited about the development and commercial prospects of our novel platform in various therapeutic applications, particularly in the ophthalmology sector. Glaukos is a world-class ophthalmic company, and we couldn’t envision a more compelling licensing partner to advance our platform as a potential solution for the many patients suffering from these challenging conditions that currently have no approved treatments. - Frank Spallitta, founder and chief executive officer of Attillaps About Attillaps Attillaps is a developmental-stage pharmaceutical company pioneering novel drug platforms for the treatment of ophthalmology and dermatology conditions such as rosacea and blepharitis, with other indications of interest that include meibomian gland dysfunction, atopic dermatitis, acne vulgaris, ocular rosacea and hidradenitis suppurativa. The proprietary unique applications of these AChE inhibitors limit systemic exposure, further increasing the known safety of these molecules while effectively targeting the cutaneous inflammation. About Glaukos Glaukos is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in 2012, its next-generation iStent inject® device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

Read More

PHARMA TECH

Veeva Development Cloud Simplifies Drug Development in the Industry

Veeva Systems | May 21, 2021

A growing number of life sciences companies are adopting Veeva Development Cloud applications from Veeva Systems in an industrywide shift to streamline drug development. quite 650 companies use Veeva Development Cloud applications today, and quite 250 are leveraging multiple Veeva Vault applications across functional areas to enable and connect drug development and manufacturing teams. Veeva Development Cloud brings together suites of unified applications for clinical, regulatory, quality, and safety on one cloud platform, eliminating organizational siloes. quite 350 companies are accelerating trial execution with Vault Clinical applications, quite 250 are streamlining regulatory processes with Vault RIM, quite 350 are unifying quality management with Vault Quality, and quite 35 are improving pharmacovigilance with Vault Safety. Vault Connections in Veeva Development Cloud drive cross-functional business processes across the merchandise lifecycle. For instance, Connections enable companies to compile clinical operations and regulatory for faster submissions; quality and regulatory for simplified change control and variation management; and clinical data and operations for real-time visibility into patient enrollment. "We're dedicated to bringing innovations to plug that help the industry accelerate drug development," said Jim Reilly, vice chairman of Veeva Vault R&D. "Veeva Development Cloud is enabling customers to enhance collaboration across teams and speed the delivery of treatments to patients." About Veeva Systems Veeva is that the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves quite 975 customers, starting from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and therefore the industries it serves.

Read More

BUSINESS INSIGHTS

Sinorda Biomedicine and Porton Advanced to Fast-track the Development of Cell Therapies for Solid Tumors

Porton Advanced | April 25, 2022

Suzhou Porton Advanced Solutions Ltd. and Guizhou Sinorda Biomedicine Co. Ltd. announced a long-term strategic relationship in cell and gene therapy research and development and platform development. Porton Advanced provides plasmids, cell therapy, gene therapy, oncolytic virus, mRNA treatment, and bacterial therapy as part of an end-to-end gene and cell therapy CDMO service platform. Sinorda Biomedicine focuses on the R&D of revolutionary drugs for digestive tract disorders, tumor immunotherapy, and oncolytic virus therapy and has multiple new drug projects in the clinical stage, thanks to its extensive expertise in domestic and international new drug filing. Jiangsu Tairui Sinorda Biomedicine Pharmaceutical Technology Co. Ltd., a subsidiary, conducts pre-clinical and clinical research on tumor immune pharmacology and efficacy. Under the terms of the agreement, Porton Advanced will help Sinorda Biomedicine speed up the development, production, and registration of breakthrough cell therapies, such as its T-cell immunotherapy product for colorectal cancer, SND002 and other pipelines. Sinorda Biomedicine will partner with Porton Advanced to support its cell and gene therapy R&D and production. The first collaborative initiative, SND002, has been approved for Phase II clinical trials in Europe. The product had previously been recognized by the Chinese National Science and Technology Major Project for "the Breakthrough New Drugs." The beginning of this key initial initiative allows Porton Advanced and Sinorda to combine resources and expertise, promising increased synergy in the clinical development and approval of Sinorda's SLN-T program. "Sinorda Biomedicine has a proven track record in drug development in China, US and Europe. The company possesses great expertise in immunology and oncolytic viruses, as well as cutting-edge immune functional assays, technologies, and capabilities. I am excited to see how our end-to-end cell and gene therapy CDMO platforms and quality systems can complement these capabilities and enhance Sinorda's pipeline. Supporting Sinorda's development, production and regulatory filing and accelerating its cell therapy drugs to market is a great cause and a great opportunity. We look forward to the opportunity to help Sinorda establish advanced therapies that benefit patients globally." Dr. Yangzhou Wang, CEO of Proton Advanced

Read More